Spontaneous Splenic Rupture in a Patient With Recent Use of Performance-Enhancing Compounds: A Case Report and Literature Review.
This case underscores the potential risks of performance-enhancing compounds like MK-677 and RAD-140, particularly in relation to splenic health. Clinicians should be aware of the possibility of atraumatic splenic rupture in patients using these substances.
Where it sits
this study against the rest of the mk-677 (ibutamoren) corpusSummary and findings
This case report details a 54-year-old male who experienced atraumatic splenic rupture after recent use of MK-677 (ibutamoren) and RAD-140 (testolone). The patient underwent splenic artery embolization followed by total splenectomy due to a large perisplenic hematoma. The report discusses the potential role of performance-enhancing compounds in precipitating splenic complications.
Abstract
Atraumatic splenic rupture (ASR) is a rare but life-threatening surgical emergency that most commonly occurs in pathologically abnormal spleens. We present a unique case of ASR in a middle-aged man with recent use of performance-enhancing compounds, managed with both embolization and surgery. This case highlights an unusual potential contributing risk factor and underscores the importance of prompt diagnosis and definitive management of ASR. A 54-year-old male presented to the emergency department with acute left upper quadrant abdominal pain and vomiting. Notably, he had recently been using MK-677 (ibutamoren), a growth hormone secretagogue, and RAD-140 (testolone), a selective androgen receptor modulator (SARM), for bodybuilding purposes. The patient denied any history of trauma. Computed tomography revealed a large perisplenic hematoma consistent with splenic rupture. Following initial resuscitation, emergent splenic artery embolization was performed to control hemorrhage. This intervention stabilized the patient transiently; however, he ultimately required an emergency laparotomy with total splenectomy. Histopathological examination demonstrated large areas of splenic infarction, with features raising the possibility of an underlying vascular malformation. These findings underscore the importance of recognising ASR in patients with acute abdominal pain and vascular risk factors. We explore the potential and speculative role of performance-enhancing compounds in precipitating splenic complications, drawing parallels to the established association between traditional anabolic steroids and peliosis - blood-filled vascular cavities that predispose to rupture. While RAD-140 and MK-677 have not been previously linked to splenic pathology, their pharmacological effects on androgen receptor signalling and IGF-1 pathways warrant consideration as possible contributing factors, particularly in the context of a suspected pre-existing vascular malformation. Early recognition, aggressive resuscitation, and timely surgical intervention remain critical, as delayed diagnosis carries significant mortality.
Background
This paper addresses the clinical question of potential adverse effects associated with the use of performance-enhancing compounds, specifically MK-677 (Ibutamoren). Previous literature has documented various side effects of such compounds, but spontaneous splenic rupture is a rare occurrence that warrants further investigation. Understanding the risks associated with these substances is crucial for practitioners and patients alike.
Methods
This is a case report detailing the clinical presentation and outcomes of a single patient who experienced spontaneous splenic rupture. Specifics regarding the patient's demographics, dosage of MK-677, and duration of use are not provided in the abstract. The primary outcome is the occurrence of splenic rupture, with no secondary outcomes reported.
Results
Not reported in abstract.
Interpretation
The findings highlight a potential risk associated with MK-677, although the evidence is limited to a single case. Compared to existing literature on performance-enhancing compounds, this case adds a unique perspective but lacks statistical power due to the absence of larger cohort data. The implications for clinical practice are significant, as they underscore the need for caution when prescribing or using such compounds.
Key findings
- Spontaneous splenic rupture reported in a patient after recent use of performance-enhancing compounds.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Single case report with no control group.
- Lack of detailed patient history and dosage information.
- No statistical analysis or effect size reported.
- Not applicable for generalizing findings to broader populations.